Back to results
US 2024/0139267 A1Published application
Seneca valley virus (svv) cellular receptor targeted oncotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLinde MILES, John POIRIER, Charles RUDIN
Life of this patent
Estimating the term…
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Claims25
1-14. (canceled)
A method comprising:
- determining an expression level of anthrax toxin receptor 1 (ANTXR1) in a cancerous tissue from a subject having cancerous tissue;
- and
- facilitating a determination of an indication of sensitivity of the subject identified as having the cancerous tissue to a treatment with a Seneca Valley Virus (SVV), a SVV derivative, a SVV mutant or a SVV variant based on a comparison of a normal expression level or an elevated expression level of ANTXR1 in the cancerous tissue from the subject compared with an expression level of ANTXR1 in a corresponding tissue from a control subject.
A kit for selecting a cancer patient for treatment with a Seneca Valley Virus (SVV), a SVV derivative, a mutant or a SVV variant, comprising:
- (1) reagents for detecting an expression level of anthrax toxin receptor 1 (ANTXR1);
- and/or
- (2) a reagent for detecting expression levels of one or more biomarkers of the α-interferon or β-interferon pathway.
Dependencies are inferred from the claim text.